Copy/Paste the key inputs from the product brochure, per guidance from Solutions. Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the…
Introduction: As one of the largest therapy markets in oncology, driven by a high incidence and long treatment durations, the treatment of metastatic HR+/HER2– breast cancer remains commercially…
Introduction: As one of the largest therapy markets in oncology, driven by a high incidence and long treatment durations, the treatment of metastatic HR+/HER2– breast cancer remains commercially…
Vascular endothelial growth factor (VEGF) inhibitors—approved agents Eylea (Regeneron) and Lucentis (Roche/Genentech), and off-label Avastin (Roche/Genentech)—are the treatment mainstays for…
Neuropathic pain (NP) is a heterogeneous disorder arising from a wide variety of diseases and conditions, and as a result, patient response to drug therapy is often unpredictable. Despite the need…
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…
Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of atopic dermatitis (AD) treatment. Last year, two new options…
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
The opioid addiction market is dominated by opioid receptor agonist therapies for the maintenance treatment of opioid addiction, most notably generic methadone and Indivior’s Suboxone Film. The…
The opioid addiction market is dominated by opioid receptor agonist therapies for the maintenance treatment of opioid addiction, most notably generic methadone and Indivior’s Suboxone Film. The…
Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…
Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…
MARKET OUTLOOK The moderate to severe AD market is at the beginning of a revolution with the recent approval of the first targeted AD biologic, Sanofi/Regeneron’s Dupixent, and a promising…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…